Aclaris Therapeutics clinical trials we track

Check company identity source

Phase 2 9 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Proportion of patients achieving ACR20 at Week 12 Time frame: Baseline to Week 12. After: Measure: Percentage of Participants Achieving ACR20 at Week 12 Description: Participants achieving American College of Rheumatology (ACR) 20 (responders) were defined as having ≥20% improvement in both the number of swollen and tender joints (66/68 joint counts) and ≥20% improvement in ≥3 of the following 5 measures: Patient's Global Assessment of Disease Activity (VAS), Patient's Assessment of Arthritis Pain (VAS), Health Assessment Questionnaire-Disability Index (HAQ-DI), Physician's Global Assessment of Disease Activity (VAS), and acute phase reactant as measured by hsCRP. Model-based estimates and 95% confidence intervals (CIs) were produced. Time frame: Week 12.

Check registry source

· 3 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 96 participants (planned). After: 110 participants (actual).

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Efficacy measured as the change from Baseline in inflammatory nodule/abscess count at Week 12.. After: Measure: Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 12.

Check registry source